The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
"Size of the claim: We believe Panthera’s claim will be based on a developed mine with a resource/reserves of c.6m oz Au. A review of mid-tier gold miners would suggest a plausible range of US$500-US$1bn. Taking the mid-point of US$750m implies US$125/oz Au. On this basis net proceeds would be US$623m after allowing for non-recourse lender commission of US$113m and reimbursement of expenses US$14m. Given the uncertainties involved and a likely lengthy legal process, we have assigned a 10% probability of success for valuation purposes. An adjustment of 2.6% has also been made for the Bhukia minority interest. The implied risk-adjusted Bhukia valuation is US$61m or 29.0p/share. Including the West African interests our valuation is US$80m or 38.0p/share, 8X the mid-December 2023 level."
Need to get confirmation from the company before drawing any conclusions. The concerted selling from 2pm onwards suggests a hedge fund or two believe that this will be a significant problem - I jumped out as better safe than sorry…
So they’ve almost doubled top line revenues but gone from a small operating profit last year to a £1.7m loss…this is mainly due to gross margin deteriorating some 7%, which is apparently in line with expectations. I’d say this is well overvalued based on the economics displayed today.
Each pair of trades is a buy & sell, they aren’t both sells…
I think the iAbra test looks fantastic, you’d have a dedicated member of staff per machine who would be responsible for taking the saliva swab & processing it through the machine. Basically an enhanced passport control, prior to leaving the country.
The sensitivity / specificity of this test is world class, and I question why Avacta haven’t released any preliminary data if it comes anywhere near this?
Bottom line is iAbra / TTG have delivered a working solution that is backed up by data & a commercial agreement with the worlds 7th largest airport. I’d be surprised if at least 10% of the worlds airports don’t follow suit, and that would be a huge commercial opportunity for TTG
The other significant advantage is that once these machines are installed competitors won’t get a look in, as switching costs will be significant & disruptive for the airport. Whereas AVCT’s test will have a multitude of competition & no switching costs at all.
Oh and are the government really going to publicly associate themselves with a test that has direct involvement from Boohoo? I’d be very surprised if they do...
What news? The fact that Bitcoin is trading at £6300? The below is an extract from the 18 April GM circular; “ In conjunction with the other measures adopted by the Board, the Board expects the Company to significantly increase revenue from mining as principal. As a result of this hardware purchase the Board currently expects to generate in the region of £500,000 of cryptoassets during May (based on a price of BTC of £3,935 (the prevailing market price as at 15 April 2019) against a cash operating cost for the Company of approximately £280,000.” So they expected to mine 127 Bitcoins in May, which at today’s prices equates to £800k per month - add to this the fact that mining capability will be increasing further in early July and you can see why they wanted to invest £100k! I’d expect ARB to move pretty quickly to 11p once word spreads of the economics and cash generation - and of Bitcoin continues to march higher we’ll be back to IPO price in bl time.
Taff, I love SKIN and what they are doing, but you know as well as me that you cannot directly compare the share price now vs 2 years ago. Market cap is what matters, we are currently sitting at £18m Mcap, the company listed on AIM with an £8m Mcap. So progress has been made, but there has been significant share price dilution along the way. Great for anyone who bought in the last year, not for the original IPO holders. At 5p our Mcap would be £48m, if sales accelerate at the rate they could or we get some major strategic collaboration then this is very feasible, but we need to see detail on costs and actual revenues before it does IMO. At present with around £500k of renenue for 2018 and no real detail on 2019 trading (other than the Rhinocloud Q1 revenue of £180k), and no detail on cash burn etc. £18m Mcap looks about right to me!
So 16 days on from stating bbsn were in self destruct mode & that a return all the way back to 0.7p was possible, the SP has fallen 17% to 1.7p. There are several reasons I think this fall will continue (all IMO) 1. Claire was the driving force behind the turnaround, she left very suddenly with no explanation which raises a multitude of questions and creates huge uncertainty 2. CFO share sale - suspect timing coming a couple of days before they announced CH had left. 3. They are more reliant on Facebook revenue now than when CH joined, any change in Facebook revenue (as stated in the final results) would have a very negative impact. I note a fall out of the top 10 on tubular labs in March, is this a blip or will it worsen? 4. Extremely negative sentiment at present 5. Combine this negative sentiment with any surprises in the half year update in late July and the market will cut this aggressively - for example if revenue falls due to lower FB views (looks likely given Q1 19 views vs Q4 18) . 6. The lack of any form of communication from the new CEO - does she really have nothing to say or is it an enforced silence??? 7. The spectre of needing to raise cash if Facebook views deteriorate or spending increases; complete speculation at present, but £5m could quickly disappear if the new CEO doesn’t run as tight a ship at CH appeared to have done. 8. General lack of communication with the market via RNS - incredible lack of PR, especially regarding APAC, since they announced the Tencent deal last September. 9. Significant shareholders (CH, Invesco) have sold recently, and any selling without buying pressure would decimate the price. At present, I literally see no positives here, which is a huge change from only a couple of months ago. @billthebank @academy, I’m interested to hear your in depth opinion about why the above is such rubbish?
The freefloat situation here is very interesting http://www.ramblermines.com/aim26-securities.php Shows: CE Mining II Rambler Limited: 66.3% Lombard Odier: 15.1% Aether Real Assets: 10% Total 91.4% Plus the RNS on April 17th that showed Cambridge Global Asset Management at 4.25% (presumably they were one of the minority participants in the placing) This gives a total of 95.65% owned by 4 entities. Leaving a 4.35% free float, or 1,296,411,642 * 0.0435 = 56,393,906 shares. Volume of 21m over the last 3 days, so 38% of free float traded, knowing this its easy to understand the 177% spike on Tuesday. I’d imagine the new CEO will be keen to publish the exploration results ASAP to capitalise on the the improved sentiment, and a short term target of 5p/£60m market cap seems sensible at this point in time, pending a move to cash flow positive.
Gary1960, which figures have you seen? I must admit I was surprised it was that low, but I also know that the list on the website only includes >3% holders, on page 3 of the below document it has Pershing Nominees at 16.24% and The Bank of New York Nominees at 12.5% http://www.blockenergy.co.uk/wp-content/uploads/2019/03/block_energy_corporate_presentation.pdf
Looks to me like a simple answer to the recent drop - the 3.6m warrants exercised on the 1st May have clearly been sold. And who can blame the holder for making a 400% gain?! The best thing about Block is it’s low free float, according to Stockpoedia it’s just 6.47% which explains the meteoric rise over the last month.
So true, I’ll be very surprised if this doesn’t test 1.8 - 2p in advance of the meeting next week!
Risk Assesor, you are the most obvious/stupid troll I’ve seen for some time. They raised £2.3m last month so absolutely no need for a placing, but then clearly you know that unless you are truly idiotic?
This is an institution to institution transfer, I’ve seen it on a few shares this year, await the TR1 before drawing any conclusions, but the net shares bought sold is pretty much zero - hence why the ask is already dropping back down...
£210k trade @ 29p showing as a buy from close yesterday... Clearly this is a worked sell though going by the share price action. The dip around midday yesterday was caused by someone selling 60k’s worth a few hours after buying, so nothing to do with the seller. Decent volume today & a 6% move in the right direction. A licensing deal with a decent up from payment would be transformational right now, given the recent news flow it wouldn’t be a huge surprise either.
I must say this report sums up the situation very well, massive upside from here - 765% to be precise (225p target vs 26p current). https://www.hardmanandco.com/wp-content/uploads/2019/04/DNL-Interim-update-25-April-2019.pdf “Based on our clearly stated assumptions, the net present value of the cashflows that could be generated from DNL’s first two products alone equates to £248m. Risk- adjustment to take account of their different stages of development in different territories reduces this to £139m, or 225p per share.” “Whichever valuation method is used, there appears to be significant upside potential for the stock. However, the current share price remains dogged by the unexpected outcome of the Phase III trial in Europe with Chronocort, despite the fact that the EMA has seen the data, and paved the way for a regulatory submission later this year. The share price also reflects the fact that the company will require more capital in 2019 in the absence of any significant licensing deals. DNL’s US competitors, shown in the competitive analysis above, are cash-rich and looking for complementary endocrine products. Therefore, failure of the UK market to recognise the full potential value could see the emergence of a predator.”
IC link to the story that’s freely available; xhttps://www.investorschronicle.co.uk/shares/2018/06/08/sink-or-swim/?plckFindCommentKey=CommentKey:19ee0795-b83b-40c2-96f6-47525bd4e524
Good spot Trescareful, full IC text below; “Founded out of the University of Sheffield in 2004, Diurnal (DNL) is focused on developing therapies for the treatment of rare and chronic hormone illnesses. Its lead drug, Alkindi – for paediatric adrenal insufficiency – has been approved in Europe and is due to begin a pivotal clinical trial in the US. Sink: Management has taken the higher-risk route and decided to commercialise Alkindi itself in Europe. High-risk and expensive clinical trials are still ongoing in the US and Europe. The share price is currently supported by the potential for Alkindi. Although the drug has proved its efficacy in clinical trials, management will still have to persuade individual European governments to prescribe the drug. Sales forecasts are only moderate in 2018, and losses are expected to widen until 2019. Swim: Diurnal has further drugs in clinical development in Europe and the US. Chronocort – for adult adrenal illness – is expected to be launched in Europe in 2020 and in the US the following year. Alkindi’s US trials are relatively low risk as the drug has already proved effective in Europe. A recent £10m fundraising has provided capital for the European Alkindi launch and further support for clinical trials. Management is open to partnerships with larger drugs companies. Diurnal is a prime example of a biotech company that has got everything right. Venture capital funding helped the drugs through their earliest, highest-risk stages of development and Aim investors have been called upon to support the final stages of development. The group is operating in an under-served part of the global healthcare market, which means its drugs shouldn’t encounter much competition and have been given long-term patent protection. As with all early-stage biotech companies, risks remain, but these are beginning to shift from research and development hazards to those associated with commercialisation. The long-term outlook is good thanks to the strong drugs pipeline and management’s decision to work with partners to market the drugs in the tough US healthcare market. Swim.” Written on 8th June 2018 when the mid price was 194p... apparently the share price wasn’t underpinned by Alkindi! Truly crazy that it’s got this low.
This actually reminds me an awful lot of STX - it dropped from 170p in May 2017 down to 15p in April 2018, in hindsight it was a screaming buy down there but nobody (myself included) bought and held for the five bagger!) I feel that DNL is in the same boat, with the string of positive RNS’s in recent weeks plus the promise of many more to come (just read the half year report, it’s stunning). Yes they need to raise some cash in Q4, but you can’t think for one minute that existing investors will want to be diluted at 25p given the progress that’s been made since the March 2018 raise at 190p! Ideally, they’ll agree a partnership similar to STX where they get a significant up front fee in exchange for exclusive distribution across the US/Japan. They already have UK, Germany, Scandinavia & now Australia, so it seems a matter of time for the remaining markets?